SCHEMBL3814746

SCHEMBL3814746

CNc1ccc([N+](=O)[O-])c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.55
CTSB P07858 4/20 0.55
AKR1C4 P17516 2/20 0.50
AKR1C3 P42330 2/20 0.50
AKR1C2 P52895 2/20 0.50
AKR1C1 Q04828 2/20 0.50
AR P10275 2/20 0.50
ALDH1A1 P00352 3/20 0.48
IDO1 P14902 1/20 0.48
HTT P42858 1/20 0.47
HCAR3 P49019 1/20 0.46
CDC25B P30305 1/20 0.46
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.42
MEN1 O00255 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28307478 0.82 TDP1 (0.52) TDP1CTSBAKR1C4AKR1C3AKR1C2
SCHEMBL7788656 0.82 TDP1 (0.80) TDP1CTSBARALDH1A1HTT
SCHEMBL8297399 0.81 TDP1 (0.55) TDP1CTSBAKR1C4AKR1C3AKR1C2
SCHEMBL645403 0.81 RXFP1 (0.58) TDP1CTSBAKR1C4AKR1C3AKR1C2
Hydrochloric Acid SCHEMBL9081792 0.80 TDP1 (0.53) TDP1CTSBAKR1C4AKR1C3AKR1C2
SCHEMBL9325996 0.79 AKR1C4 (0.70) TDP1CTSBAKR1C4AKR1C3AKR1C2
SCHEMBL9778189 0.77 IDO1 (0.73) TDP1ALDH1A1IDO1MAPTMAPK1
SCHEMBL30336868 0.77 IDO1 (0.73) TDP1ALDH1A1IDO1MAPTMAPK1
SCHEMBL30198949 0.76 TDP1 (0.60) TDP1ALDH1A1HCAR3CDC25BMAPT
SCHEMBL230874 0.76 TDP1 (0.60) TDP1ALDH1A1HCAR3CDC25BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS JANSSEN-CILAG (FR) 2018-06-21 US disclosed
EP-1789039-A4 S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE ARDEA BIOSCIENCES INC (US) 2009-08-05 EP disclosed
EP-1789039-A2 S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE Ardea Biosciences, Inc. (US) 2007-05-30 EP disclosed
WO-2006026356-A2 S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE ARDEA BIOSCIENCES, INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170909-A1 PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS MALT1, PPP3R1, SQSTM1 TDP1 428/4885CTSB 1195/4885AKR1C4 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.